Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sometimes, it’s hard to know who or what to believe. Such is the case when it comes to the ongoing U.S. Securities and Exchange Commission (SEC) probe into Cassava Sciences (NASDAQ: SAVA ). As the biopharm...
Summary Success for BIIB and ESALY in Alzheimer's disease provided no sustained rally for SAVA. Clouds of uncertainty are still hanging over SAVA's potential Alzheimer's therapeutic, simufilam. The company will need to boost its own stock, but investors might have to wait a wh...
Summary This is a highly speculative bet. There has been a constant litany of accusations of wrongdoing on the science. There have been several recent positive developments. The data readouts will be massive catalysts. This is such a binary investment you will either d...
Retail interest in Cassava Sciences (NASDAQ:SAVA) remains far from over. The stock gained more than 6.7% on Wednesday, catapulting it to a 76% increase in value in a month. The Wednesday gains came as a result of improved sentiment in Biotech stocks Biogen Inc. and Eisai Co. Ltd...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Silo Pharma (NASDAQ: SILO ) stock is in the news Wednesday as investors react to the company uplisting shares . This saw shares of SILO stock switch from the OTC Marke...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Sundry Photography / Shutterstock.com Taiwan Semiconductor (NYSE: TSM ) stock isn’t doing so hot Wednesday on reports that Apple (NASDAQ: AAPL ) is decreasing production for the iPhone 14. ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips There’s been some drama surrounding Cassava Sciences (NASDAQ: SAVA ) recently. First, there was a report stating that the Securities and Exchange Commission, or SEC, cleared Cassava Sciences of charges o...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of Cassava Sciences (NASDAQ: SAVA ) are down by over 15% following the previous day’s gain of 35%. Yesterday, the Securities and Exchange Commission (SEC) announced that it had closed its case on Cassa...
Summary Initiation of a phase 3 program open-label extension study using Simufilam for patients with Alzheimer's Disease is expected in 2nd half of 2022. An ongoing long-term open label study, initiated in March of 2020 is ongoing; Dosing completion is expected Q4 of 2022 and resu...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Deleted: Despite a significant down day for the S&P 500, shares of Cassava Sciences (NASDAQ: SAVA ) closed higher by 35%. That’s because the Securities and Exchange Commission (SEC) has closed its case on...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
-0.13% Change Percent:
Cassava Sciences Inc. Company Name:
SAVA Stock Symbol:
NYSE Market:
Cassava Sciences Inc. Website:
Cassava Sciences, Inc. (NASDAQ: SAVA) is one of today's top gainers. The company's shares have moved 24.9% on the day to $12.59. Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...